42 research outputs found
First-trimester screening for fetal chromosomal abnormalities. Preliminary results
No full textWe have started a multicentre trial to study the possibilities of first-trimester maternal serum screening for fetal chromosomal abnormalities. Maternal blood samples were obtained before 13 weeks of gestation. We present the preliminary results of the first 950 patients on alpha-fetoprotein (AFP). Results on cancer antigen 125 (CA 125) in Down's syndrome and normal pregnancies are also presented. We conclude that the results on AFP are promising and that CA 125 might be predictive for fetal Down's syndrome
Effects on (neuro) developmental and behavioral outcome at 2 years of age of induced labor compared with expectant management in intrauterine growth-restricted infants: long-term outcomes of the DIGITAT trial
No full textPresented at the 32nd annual meeting of the Society for Maternal-Fetal Medicine, Dallas, TX, Feb. 6-11, 2012.Objective: We sought to study long-term (neuro)developmental and behavioral outcome of pregnancies complicated by intrauterine growth restriction at term in relation to induction of labor or an expectant management. Study Design: Parents of 2-year-old children included in the Disproportionate Intrauterine Growth Intervention Trial at Term (DIGITAT) answered the Ages and Stages Questionnaire (ASQ) and Child Behavior Checklist (CBCL). Results: We approached 582 (89.5%) of 650 parents. The response rate was 50%. Of these children, 27% had an abnormal score on the ASQ and 13% on the CBCL. Results of the ASQ and the CBCL for the 2 policies were comparable. Low birthweight, positive Morbidity Assessment Index score, and admission to intermediate care increased the risk of an abnormal outcome of the ASQ. This effect was not seen for the CBCL. Conclusion: In women with intrauterine growth restriction at term, neither a policy of induction of labor nor expectant management affect developmental and behavioral outcome when compared to expectant management.Linda van Wyk, Kim E. Boers, Joris A.M. van der Post, Maria G. van Pampus, Aleid G. van Wassenaer, Anneloes L. van Baar, Marc E.A. Spaanderdam, Jeroen H. Becker, Anneke Kwee, Johannes J. Duvekot, Henk A. Bremer, Friso M.C. Delemarre, Kitty W.M. Bloemenkamp, Christianne J.M. de Groot, Christine Willekes, Frans J.M.E. Roumen, Jan M.M. van Lith, Ben W.J. Mol, Saskia le Cessie, Sicco A. Scherjon, for the DIGITAT Study Grou
Pregnant women at increased risk of adverse perinatal outcomes: A combination of less healthy behaviors and adverse psychosocial and socio-economic circumstances
No full textResearch into fetal development and medicin
Ethnic differences in perinatal mortality. A perinatal audit on the role of substandard care
No full textEthnic differences in perinatal mortality. A perinatal audit on the role of substandard care
No full textFirst trimester maternal serum concentrations of fetal antigen 2 in normal pregnancies and those affected by trisomy 21
No full textSerum concentrations of fetal antigen 2 (FA-2), the amino-propeptide of the al chain of collagen type I, were measured in peripheral blood from women with normal (n = 234) and trisomy 21 affected (n = 14) pregnancies between 9 and 11 weeks gestation. Serum FA-2 concentrations were seen to be stable throughout this period, and though raised FA-2 concentrations were seen at the 10th week of gestation, a statistically significant difference between normal and trisomy 21 affected pregnancies was not found overall. Therefore it seems unlikely that FA-2 has a role in first trimester screening for trisomy 21, despite the fact that significantly higher FA-2 concentrations in trisomy 21 and significantly lower concentrations in trisomy 18 had been previously demonstrated in amniotic fluid in the second trimester.</p
Ethnic differences in perinatal mortality. A perinatal audit on the role of substandard care
No full textWomens' preference in Down syndrome screening
No full textObjective To determine the knowledge of pregnant women about prenatal tests. and what tests they would choose if offered. Also, the preference of pregnant women for second-trimester or first-trimester screening was assessed. Patients and methods Pregnant women receiving antenatal care in a decentralized primary care system (n = 80). and pregnant women that were offered a prenatal diagnosis Lit the Academic Medical Centre (n = 195), were asked to complete a questionnaire. Results The response rate was over 80%. Most women in both groups preferred a screening test for Down syndrome to be performed in the first trimester of pregnancy. A combination of nuchal translucency measurement and first-trimester serum screening was the option of choice. The screening possibilities For Down syndrome were less well known to the women in the low-risk group compared with the women in the high-risk group. The offer of a prenatal screening test would have been declined by more than 30% of women at low risk For carrying a fetus with Down syndrome. Conclusions Our results Show that women prefer screening for Down syndrome to be performed in the first trimester of pregnancy Using both serum and ultrasound tests. In women at low risk for Down syndrome the knowledge of prenatal screening methods was less. as well as the acceptance of prenatal screening being, lower. Copyright (C) 2002 John Wiley Sons, Ltd
First trimester maternal serum concentrations of fetal antigen 2 in normal pregnancies and those affected by trisomy 21
No full textSerum concentrations of fetal antigen 2 (FA-2), the amino-propeptide of the al chain of collagen type I, were measured in peripheral blood from women with normal (n = 234) and trisomy 21 affected (n = 14) pregnancies between 9 and 11 weeks gestation. Serum FA-2 concentrations were seen to be stable throughout this period, and though raised FA-2 concentrations were seen at the 10th week of gestation, a statistically significant difference between normal and trisomy 21 affected pregnancies was not found overall. Therefore it seems unlikely that FA-2 has a role in first trimester screening for trisomy 21, despite the fact that significantly higher FA-2 concentrations in trisomy 21 and significantly lower concentrations in trisomy 18 had been previously demonstrated in amniotic fluid in the second trimester
